← Back to Search

Statins

High-Dose Statins for Low HDL Cholesterol

Phase 4
Waitlist Available
Led By Craig D Williams
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Screening visit LDL-c or non-HDL-c (for patients with TG 200-500 mg/dL) in range requiring therapy based on National Cholesterol Education Program (NCEP) guidelines
18 years of age or older
Must not have
Known history or diagnosis of clinical hepatic failure (example: variceal bleeding, ascites, INR>1.3)
Age < 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial
All Individual Drugs Already Approved
Approved for 30 Other Conditions
Drug Has Already Been Approved
No Placebo-Only Group

Summary

This trial is designed to study the effects of two commonly used statin medications on HDLc concentrations.

Who is the study for?
This trial is for adults with low HDL (good cholesterol) levels who need treatment based on guidelines. They must have a primary care provider, working phone number, and not be pregnant or breastfeeding. People taking certain other drugs, with unstable heart disease, very high triglycerides, liver issues, heavy alcohol use or known allergies to the study drugs cannot join.
What is being tested?
The trial tests two high-dose statin medications—80mg of simvastatin and atorvastatin—to see how they affect HDL cholesterol levels and particle functionality. It's part of research to understand if higher HDL can help reverse artery plaque buildup.
What are the potential side effects?
Potential side effects include muscle pain or weakness, liver problems indicated by abnormal blood tests, digestive issues like nausea or constipation, increased blood sugar levels which may lead to diabetes risk in some patients.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My bad cholesterol levels are high enough to need treatment, according to national guidelines.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of severe liver problems.
Select...
I am under 18 years old.
Select...
I am taking medication that interacts with Zocor or Lipitor.
Select...
I haven't had any recent heart problems or unstable chest pain.
Select...
I have been diagnosed with HIV/AIDS.
Select...
I am allergic to or cannot take atorvastatin or simvastatin.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 30 Other Conditions
This treatment demonstrated efficacy for 30 other conditions.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: 2Active Control1 Intervention
Atorvastatin 80 mg
Group II: 1Active Control1 Intervention
Aimvastatin 80 mg

Find a Location

Who is running the clinical trial?

Indiana UniversityOTHER
1,040 Previous Clinical Trials
1,219,984 Total Patients Enrolled
Oregon State UniversityOTHER
50 Previous Clinical Trials
8,354 Total Patients Enrolled
Oregon Health and Science UniversityLead Sponsor
1,006 Previous Clinical Trials
7,414,032 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
4,027 Previous Clinical Trials
5,188,723 Total Patients Enrolled
Craig D WilliamsPrincipal InvestigatorOregon Health and Science University

Media Library

Atorvastatin (Statins) Clinical Trial Eligibility Overview. Trial Name: NCT00736463 — Phase 4
High-Density Lipoprotein Research Study Groups: 2, 1
High-Density Lipoprotein Clinical Trial 2023: Atorvastatin Highlights & Side Effects. Trial Name: NCT00736463 — Phase 4
Atorvastatin (Statins) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00736463 — Phase 4
~4 spots leftby Dec 2025